Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines

Natacha Madelon, Kim Lauper, View ORCID ProfileGautier Breville, Irène Sabater Royo, Rachel Goldstein, View ORCID ProfileDiego O. Andrey, Alba Grifoni, Alessandro Sette, Claire-Anne Siegrist, Axel Finckh, Patrice H. Lalive, View ORCID ProfileArnaud M. Didierlaurent, Christiane S. Eberhardt
doi: https://doi.org/10.1101/2021.07.21.21260928
Natacha Madelon
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Lauper
2Department of Medicine, Division of Rheumatology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gautier Breville
3Department of Neurosciences, Division of Neurology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gautier Breville
Irène Sabater Royo
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Goldstein
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego O. Andrey
4Department of Diagnostics, Division of Laboratory Medicine; University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diego O. Andrey
Alba Grifoni
5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Sette
5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, USA
6Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire-Anne Siegrist
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
7Center for Vaccinology and Department for Paediatrics, Geneva University Hospitals, Emory University School of Medicine, Atlanta, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Axel Finckh
2Department of Medicine, Division of Rheumatology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice H. Lalive
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
3Department of Neurosciences, Division of Neurology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnaud M. Didierlaurent
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arnaud M. Didierlaurent
  • For correspondence: Arnaud.didierlaurent@unige.ch Christiane.Eberhardt@unige.ch
Christiane S. Eberhardt
1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
7Center for Vaccinology and Department for Paediatrics, Geneva University Hospitals, Emory University School of Medicine, Atlanta, USA
8Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Arnaud.didierlaurent@unige.ch Christiane.Eberhardt@unige.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Patients treated with anti-CD20 therapy are particularly at risk of developing severe COVID-19, however little is known regarding COVID-19 vaccine effectiveness in this population. This study assesses humoral and T-cell responses to mRNA-based COVID-19 vaccines in patients treated with rituximab for rheumatic diseases or ocrelizumab for multiple sclerosis (n=37), compared to immunocompetent individuals (n=22). SARS-CoV-2-specific antibodies were detectable in only 69.4% of patients and at levels that were significantly lower compared to controls who all seroconverted. In contrast to antibodies, Spike (S)-specific CD4+ T cells were equally detected in immunocompetent and anti-CD20 treated patients (85-90%) and mostly of a Th1 phenotype. Response rates of S-specific CD8+ T cells were higher in ocrelizumab (96.2%) and rituximab-treated patients (81.8%) as compared to controls (66.7%). Vaccine-specific CD4+ and CD8+ T cells were polyfunctional but expressed more IL-2 in patients than in controls. In summary, our study suggests that patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA COVID-19 vaccines, despite impaired humoral responses. This could play an important role in the prevention of severe COVID-19.

Competing Interest Statement

A.S. is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxfordimmunotech, and Avalia. A.D. is consultant for Speranza. All of the other authors declare no competing interests. LJI has filed for patent protection for various aspects of vaccine design and identification of specific epitopes.

Funding Statement

This work was supported by the HUG private Foundation, the NIH NIAID contract no. 75N9301900065 and by the Giorgi-Cavaglieri foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This prospective observational study was conducted at the Geneva University Hospitals (HUG), Switzerland according to the principles of Good Clinical Practice and was approved by the Geneva Cantonal Ethics Commission (2021-00430).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# co-senior authorship

Data Availability

All data are available in text, figures or as supplementary material. Raw data files (anonymized data)included in this manuscript may be available upon request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 23, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines
Natacha Madelon, Kim Lauper, Gautier Breville, Irène Sabater Royo, Rachel Goldstein, Diego O. Andrey, Alba Grifoni, Alessandro Sette, Claire-Anne Siegrist, Axel Finckh, Patrice H. Lalive, Arnaud M. Didierlaurent, Christiane S. Eberhardt
medRxiv 2021.07.21.21260928; doi: https://doi.org/10.1101/2021.07.21.21260928
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines
Natacha Madelon, Kim Lauper, Gautier Breville, Irène Sabater Royo, Rachel Goldstein, Diego O. Andrey, Alba Grifoni, Alessandro Sette, Claire-Anne Siegrist, Axel Finckh, Patrice H. Lalive, Arnaud M. Didierlaurent, Christiane S. Eberhardt
medRxiv 2021.07.21.21260928; doi: https://doi.org/10.1101/2021.07.21.21260928

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (894)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8744)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1844)
  • Geriatric Medicine (175)
  • Health Economics (386)
  • Health Informatics (1281)
  • Health Policy (642)
  • Health Systems and Quality Improvement (488)
  • Hematology (206)
  • HIV/AIDS (387)
  • Infectious Diseases (except HIV/AIDS) (10519)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (216)
  • Neurology (1744)
  • Nursing (100)
  • Nutrition (264)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (262)
  • Pediatrics (553)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1836)
  • Public and Global Health (3962)
  • Radiology and Imaging (649)
  • Rehabilitation Medicine and Physical Therapy (340)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (105)
  • Urology (78)